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a b s t r a c t
Early rule-in and rule-out of non-ST-segment elevation myocardial infarction (NSTEMI) is a
challenge. In patients with inconclusive ﬁndings on ECG, cardiac biomarkers play a crucial
role in the diagnosis. The introduction of the new high-sensitive cardiac troponin test
(hs-TnI assay) has changed the landscape of NSTEMI diagnosis.
The new hs-TnI assay can detect troponin values at a lower level compared with a
contemporary cardiac troponin (cTn) assay. The hs-cTnI assay has a coefﬁcient of variation
of ≤10%, well below the 99th percentile value. It reduces the time to diagnose acute
myocardial infarction from 6 h to 3 h. A recent study has demonstrated that hs-cTnI can
further reduce the time to 1 h in 70% of all patients with chest pain.
The European Society of Cardiology 2015 guidelines recommend including a second
sample of hs-cTnI within 3 h of presentation This increases the sensitivity of the hs-TnI
assay from 82.3% (at admission) to 98.2% and negative predictive value from 94.7%
(at admission) to 99.4%. Combining the 99th percentile at admission with serial changes
* Corresponding author.
E-mail address: jjdalal@hotmail.com (J.J. Dalal).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/ihjhttp://dx.doi.org/10.1016/j.ihj.2016.03.013
0019-4832/# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
in troponin increases the positive predictive value to rule in acute coronary syndrome from
75.1% at admission to 95.8% after 3 h.
The 2015 ESC Guidelines recommend the use of a rapid rule out protocol (0 h and 1 h)
when hs-cTnI with a validated 0 to1 h algorithm is available.
Training and displaying the clinical algorithm depicting the role of hs-TnI assay in acute
cardiac care units and in EDs are an efﬁcient way to deliver the new standard of care to
patients. Compared with contemporary troponin assays, the hs-cTn assay accelerates the
diagnostic pathway to 0–1 h, thus reducing the time for diagnosis of NSTEMI and hence, its
management.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Acute coronary syndrome (ACS), comprising ST-segment
elevation myocardial infarction (STEMI), non-ST-segment
elevation myocardial infarction (NSTEMI) and unstable
angina, is the most common cause of mortality in patients
with CAD.1 Studies from India and China have reported that
STEMI remains more frequent than NSTEMI.2–4 According to
the CREATE registry, the incidence of STEMI (60.6%) was
greater than that of NSTEMI (39.4%) in India, which is in
contrast to data from the developed countries.5 A recent
study by Sharma et al.6 also reported that the incidence of
STEMI (63.7%) was higher than that of NSTEMI (11.3%). This
study, conducted in ACS patients of south Indian population,
noted that ACS occurred 10 years earlier among Indians
compared with western population. The discrepancies in the
incidence of STEMI and NSTEMI can be partly attributed to
factors such as more subtle or atypical symptoms of NSTEMI
in older patients and in women and non-availability of more
sensitive cardiac biomarkers, thereby reduced the number of
NSTEMI cases diagnosed.7 In this background, cardiac
biomarkers have emerged as integral components in the
diagnosis of NSTEMI.
2. Implications of early diagnosis of NSTEMI
Despite advances in therapeutic strategies, the rate of acute
myocardial infarction (AMI) and consequent mortality remain
high in patients with ACS. Therefore, timely diagnosis,
especially early ruling in or ruling out of MI is of utmost
importance.7 Early rule-in of AMI prevents the mistaken
discharge of patients with AMI with normal ﬁndings on initial
ECG and also helps in early initiation of effective evidence-
based therapy.8,9 An early rule-out of AMI prevents inadver-
tent admission of patients without ACS and facilitates early
discharge of patients and thereby decreases the unwarranted
healthcare burden.10 Moreover, a delay in rule-in of AMI may
increase the risk of complications and mortality, particularly
in patients with pre-existing CAD. Similarly, a delay in rule-out
of AMI may contribute to prolonged assessments, unnecessary
investigations, increased patient anxiety, as well as over-
crowding in the emergency department.113. Role of cardiac biomarkers in patients with
nondiagnostic ECGs
Cardiac biomarkers are crucial to establish the diagnosis of
ACS, especially in patients with nondiagnostic ﬁndings on
ECG.12 Cardiac biomarkers used include creatinine kinase,
myoglobin, cardiac troponin (cTn), brain natriuretic peptide,
lactate dehydrogenase, aspartate aminotransferases, and
heart fatty acid binding protein.13 Cardiac troponin: Cardiac
troponins T and I (cTnT and cTnI) are the most sensitive and
cardiac speciﬁc biomarkers currently available to diagnose
non-STACS,10,11 owing to the tissue-speciﬁc expression of
cTnT and cTnI in the myocardium.14 However, in patients with
chronic renal failure, cTnI has greater speciﬁcity for myocar-
dial injury than cTnT.15 A diagnosis of AMI is based on the
detection of a rise and/or fall of cTn along with the presence of
characteristic symptoms, and/or ECG or imaging evidence of
acute myocardial ischemia.13,16 The cut-off value of cTn to
diagnose MI is deﬁned as a concentration exceeding the 99th
percentile of a normal reference population (i.e. upper
reference limit [URL]) using an assay with an imprecision
(coefﬁcient of variation, CV) ≤10% at the URL.16 However, the
contemporary cTn assays cannot measure cTn levels at low
concentrations corresponding to the 99th percentile value of a
normal reference population.17 Thus, they lack the precision
criteria to diagnose AMI. Consequently, the high-sensitivity
cardiac troponin (hs-cTn) assays were developed to meet the
requirements of analytical precision and overcome the short-
comings associated with contemporary cTn assays.18
4. Entry of high-sensitive cardiac troponin has
changed the landscape of NSTEMI
According to the International Federation of Clinical Chemistry
(IFCC) Task Force Recommendation on Analytical Character-
istics, an assay is considered high sensitive if the total
imprecision (i.e. CV) at the 99th percentile value is ≤10%, and
measurable concentrations below the 99th percentile can be
attained at a concentration value above the assay's limit of
detection (LOD) in at least 50% (and ideally >95%) of healthy
individuals.19 The hs-cTn assays are capable of measuring cTn
in single digit ranges of nanograms per liter; some research
Table 1 – Characteristics of the Abbott ARCHITECT hs-cTnI and Roche Elecsys hs-cTnT assay.
Company/platform/assay Cardiac troponin concentration at
LOD (ng/L) 99th percentile ng/L (CV) 10% CV concentration (ng/L)
Abbott ARCHITECT hs-cTnI assay 1.2 16 (5.6%) 3
Roche Elecsys hs-cTnT assay 5.0 14 (8%) 13
LOD: limit of detection; CV: coefﬁcient of variation.
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than 1 ng/L. Thus, with the use of hs-cTn assays, the 99th
percentile of cTn levels can be calculated more precisely in the
reference population, which is the recommended URL. Addi-
tionally, the hs-cTn assays measure the URL with a CV of <10%.
Small differences in cTn levels over time can be detected more
easily due to the high precision of hs-cTn assays.20
In a recent publication by Love et al. the two high-
sensitivity assays are discussed, one by Abbott Diagnostics
and the other by Roche Diagnostics, an overview of which is
presented in Table 1.21 The hs-cTn assays are advantageous
when compared with contemporary cTn assays in that they
are associated with increased sensitivity, higher diagnostic
accuracy for early diagnosis. Several hs-cTn assays with
different values for the 99th percentile URL as deﬁned by the
manufacturer are currently available in the market.22 Accord-
ing to the manufacturer's speciﬁcations, the Abbott ARCHI-
TECT STAT hs-cTnI assay can detect troponin I in 96% of the
reference population and has a turnaround time (TAT) of
16 min.3 The Roche Elecsys high-sensitive troponin T assay
can detect troponin T in 25% of the reference population and
has an estimated TAT of 18 min.23,13 It is also available as a
STAT version, which has a short TAT of 9 min. Since the 99th
percentile value and the rate of detection of cardiac troponin in
reference population differ for each assay, the name of the test
kit or the assay instrument used should be mentioned as assay
references.
A prospective multicenter study by Gimenez et al. has
demonstrated that the ARCHITECT STAT hs-cTnI assay
has a signiﬁcantly higher diagnostic accuracy for NSTEMI,
when compared with Roche hs-cTnT assay among patients
presenting to the ED within 3 h of chest pain onset. Among
early presenters (representing 25% of overall study cohort),
the area under the curve (AUC) at presentation for hs-cTnI
was 0.92; 95% conﬁdence interval (CI): 0.89–0.94 when
compared with the AUC for hs-cTnT of 0.89; 95% CI: 0.86–
0.91 (p = 0.019).24
Evidence indicates major differences in the diagnosis,
management and treatment outcomes of ACS between men
and women, with early and late mortality due to ACS being
reported to be higher in women than in men. The under
diagnosis of MI in women and the inequalities in treatment
and outcomes might be attributed to the use of a single
diagnostic cut off with contemporary cTn assays. The
ARCHITECT STAT hs-cTnI is the only assay that identiﬁes
potentially important differences in the reference range for
troponin between men and women.22,25 In a prospective
cohort study by Shah et al., the use of new hs-cTnI assay with
a sex-speciﬁc diagnostic threshold (for women: 16 ng/L) led to
an increase in the number of women diagnosed with type 1 MIfrom 16% (with the generic threshold of 26 ng/L) to 22%. This
may change the landscape of ACS therapy in women, who so
far are less likely to receive evidence-based therapy due to
under diagnosis.26
The ESC 2015 guidelines for the management of
ACS recommend including a second sample within 3 h
of presentation, as with the use of a second sample, the
sensitivity of hs-cTn assays for MI approaches 100%.18 In a
study by Keller et al., inclusion of a second sample at 3 h after
admission increased the sensitivity of the hs-cTnI assay from
82.3% (at admission) to 98.2% and negative predictive value
from 94.7% (at admission) to 99.4%. Additionally, when the
99th percentile at admission was combined with serial
changes in troponin concentrations within 3 h, the positive
predictive value of hs-cTnI assay to rule in AMI increased from
75.1% at admission to 95.8% after 3 h.27
Apart from AMI, several other conditions such as conges-
tive heart failure, renal disease, myocarditis, severe infection
and musculoskeletal conditions may also be associated with
elevated cTn levels. Along with careful clinical assessment,
serial sampling is essential to differentiate AMI from these
conditions.3 The hs-cTn assays are also capable of being
detected in 50% of apparently disease-free individuals, with
some hs-cTnI assays being able to do so in as high as 90% of
this population.26
5. Protocol for early rule-out of AMI using hs-
cTnI assay
The 2015 ESC guidelines recommend the use of a rapid rule
out protocol (0 h and 1 h or 0 and 3 h) when high-sensitive
cardiac troponin test (hs-cTnI) with a validated 0 h/1 h
algorithm is available.18,28 Abbott Diagnostics has proposed
an algorithm for the early rule out of AMI (Fig. 1). The
algorithm highlights that if a patient presents to the ED with
chest pain of >6 h of onset and the hs-TnI value is below the
LOD, TIMI is ≤1 and GRACE score below 140, the patient can
be ruled out for AMI.
If the pain is <6 h of onset and the hs-TnI value is below the
99th percentile gender-speciﬁc cutoffs, a repeat sample is
recommended 3 h later. If the second value is greater than 50%
relative change value (RCV), then the patient should be
admitted for intervention. If the ﬁrst hs-TnI value is above
the gender speciﬁc cutoffs, a second sample is recommended
at 3 h. If the second hs-TnI value is also above the gender-
speciﬁc cutoffs, but without signiﬁcant RCV (RCV <50%) then
AMI can be ruled out. If the ﬁrst troponin value is 10 times the
gender-speciﬁc cutoffs, then the patient should be admitted
for intervention.
Fig. 1 – Abbott proposed algorithm for triage of NSTE-ACS (Non-ST-segment elevation acute coronary syndrome) patients
based on hs-cTn I results.
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The hs-cTn assay is associated with improved sensitivity and
precision in the diagnosis of ACS. It helps to detect changes
early, and rule out NSTEMI within 3 h. Obtaining a second
sample within 3 h of presentation improves the sensitivity to
nearly 100%. According to Gimenez et al.,24 hs-cTnI has
signiﬁcantly higher diagnostic accuracy compared to hs-cTnT.
Additionally, it is important to use only assays with gender-
speciﬁc cut off rates and thus facilitate improved diagnosis of
NSTEMI in women. As the 99th percentile value and the rate of
detection of cardiac troponin in reference population differs
for each assay, the name of the test kit or the assay instrument
used should be mentioned as assay references. Among the hs-
cTn assays available, the ARCHITECT STAT hs-cTnI assay has
a CV of 5.6% at the 99th percentile, can detect troponin I in 96%
of the reference population and has gender-speciﬁc cut off
rates.18 The enhanced sensitivity of the new hs-cTn assays
could translate into earlier intervention for patients with
conﬁrmed NSTEMI and shorter inpatient hospital stay for
patients without elevated troponin levels. The increased use of
newer hs-cTnI assay could lead to a paradigm shift in the
management of patients with NSTEMI.
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